| Nicole L Duncan, AUD | |
|
6 Telcom Dr, Bangor, ME 04401-3072 | |
| (207) 941-2850 | |
| (207) 941-2852 |
| Full Name | Nicole L Duncan |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 13 Years |
| Location | 6 Telcom Dr, Bangor, Maine |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699067553 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | AP2095 (Maine) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Penobscot Community Health Center | 0143212670 | 132 |
News Archive
The head of the nation's largest trade group for the specialty pharmacies known as compounders said he will support legislation requiring pharmacies that operate like drug manufacturers to register with the Food and Drug Administration and be subject to stricter standards enforced by the agency.
Researchers recently described a set of 11 Nbs derived from an immunized alpaca which showed high-affinity binding to the glycosylated SARS-CoV-2 spike receptor domain (RBD) in a study published in the preprint server bioRxiv.
Scientists funded by the Biotechnology and Biological Sciences Research Council have harnessed a new drug discovery tool to identify a new player in the body's insulin secretion process.
Gilead Sciences, Inc. has announced that it has begun enrolling patients in a Phase III clinical trial of its investigational antiretroviral agent elvitegravir (GS 9137), a novel oral integrase inhibitor that is being evaluated for the treatment of HIV-1 infection.
› Verified 2 days ago
| Provider Name | Penobscot Community Health Center |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1427169010 PECOS PAC ID: 0143212670 Enrollment ID: O20040819000698 |
News Archive
The head of the nation's largest trade group for the specialty pharmacies known as compounders said he will support legislation requiring pharmacies that operate like drug manufacturers to register with the Food and Drug Administration and be subject to stricter standards enforced by the agency.
Researchers recently described a set of 11 Nbs derived from an immunized alpaca which showed high-affinity binding to the glycosylated SARS-CoV-2 spike receptor domain (RBD) in a study published in the preprint server bioRxiv.
Scientists funded by the Biotechnology and Biological Sciences Research Council have harnessed a new drug discovery tool to identify a new player in the body's insulin secretion process.
Gilead Sciences, Inc. has announced that it has begun enrolling patients in a Phase III clinical trial of its investigational antiretroviral agent elvitegravir (GS 9137), a novel oral integrase inhibitor that is being evaluated for the treatment of HIV-1 infection.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicole L Duncan, AUD Po Box 1599, Bangor, ME 04402-1599 Ph: (207) 945-5247 | Nicole L Duncan, AUD 6 Telcom Dr, Bangor, ME 04401-3072 Ph: (207) 941-2850 |
News Archive
The head of the nation's largest trade group for the specialty pharmacies known as compounders said he will support legislation requiring pharmacies that operate like drug manufacturers to register with the Food and Drug Administration and be subject to stricter standards enforced by the agency.
Researchers recently described a set of 11 Nbs derived from an immunized alpaca which showed high-affinity binding to the glycosylated SARS-CoV-2 spike receptor domain (RBD) in a study published in the preprint server bioRxiv.
Scientists funded by the Biotechnology and Biological Sciences Research Council have harnessed a new drug discovery tool to identify a new player in the body's insulin secretion process.
Gilead Sciences, Inc. has announced that it has begun enrolling patients in a Phase III clinical trial of its investigational antiretroviral agent elvitegravir (GS 9137), a novel oral integrase inhibitor that is being evaluated for the treatment of HIV-1 infection.
› Verified 2 days ago
Dr. Jeannine Marie Campbell, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 905 Union St, Suite 10, Bangor, ME 04401 Phone: 207-973-7365 | |
Dawn Dufkin-britt, MS, CCC/A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 489 State St, Bangor, ME 04401 Phone: 207-973-7365 | |
Thomas M Beebe, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 6 Telcom Dr, Bangor, ME 04401 Phone: 207-941-2850 Fax: 207-941-2852 | |
Beverly Renee Mcdowell, AU.D., CCC-A Audiologist Medicare: Medicare Enrolled Practice Location: 905 Union St Ste 10, Bangor, ME 04401 Phone: 207-973-7365 | |
Mrs. Amanda Leigh Emerson, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 175 Union St, Bangor, ME 04401 Phone: 207-941-2850 Fax: 207-941-2852 | |
Cynthia L Nulton, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 6 Telcom Dr, Bangor, ME 04401 Phone: 207-941-2850 |